1. Home
  2. WSHP vs EVO Comparison

WSHP vs EVO Comparison

Compare WSHP & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WSHP

WeShop Holdings Limited Class A Ordinary Shares

N/A

Current Price

$87.02

Market Cap

1.3B

Sector

N/A

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.34

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WSHP
EVO
Founded
2021
1993
Country
British Virgin Islands
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
WSHP
EVO
Price
$87.02
$3.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
12.9K
253.2K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,110,047.00
$887,396,457.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.52
P/E Ratio
N/A
N/A
Revenue Growth
428.16
N/A
52 Week Low
$20.02
$2.84
52 Week High
$250.00
$4.80

Technical Indicators

Market Signals
Indicator
WSHP
EVO
Relative Strength Index (RSI) N/A 61.17
Support Level N/A $3.10
Resistance Level N/A $3.23
Average True Range (ATR) 0.00 0.08
MACD 0.00 0.04
Stochastic Oscillator 0.00 97.92

Price Performance

Historical Comparison
WSHP
EVO

About WSHP WeShop Holdings Limited Class A Ordinary Shares

WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the Company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: